Sialic acid sugar-carrying glycans, sialoglycans, are aberrantly expressed on many tumor
cells and have emerged as potent regulatory molecules involved in creating a tumor …

Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of receptors that
recognize sialoglycans–sialic acid containing glycans that are abundantly present on cell …

Certain pathogenic bacteria are known to modulate the innate immune response by
decorating themselves with sialic acids, which can engage the myelomonocytic lineage …

Glioblastoma (GBM) is the most aggressive form of primary brain tumor, for which effective
therapies are urgently needed. Cancer cells are capable of evading clearance by …

Siglec‐7 is a sialic acid binding receptor with inhibitory potential, expressed on human NK
cells and monocytes. It has an unusual binding preference for α2, 8‐linked disialic acids …

Interactions between sialylated glycans and sialic acid-binding immunoglobulin-like lectin
(Siglec) receptors have been recently described as potential new immune checkpoint that …

The siglec family of sialic acid-binding proteins are endocytic immune cell receptors that are
recognized as potential targets for cell directed therapies. CD33 and CD22 are prototypical …

The Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint
receptors that suppress immune cell activation upon engagement of cognate sialoglycan …

Cell surface sialosides constitute a central axis of immune modulation that is exploited by
tumors to evade both innate and adaptive immune destruction. Therapeutic strategies that …

Sialic acid-binding receptors are expressed on the surfaces of a variety of immune cells and
have complex and diverse immunoregulatory functions in health and diseases. Recent …